IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Seventeen analysts give IDEAYA a consensus rating of Moderate Buy (15 Buy, 1 Hold, 1 Sell) with an average 12‑month price target of $50.44.
• In its most recent quarter IDEAYA reported a loss of ($1.11) EPS, missing estimates by $0.10; revenue was $6.56M (above estimates) but down 39.4% year‑over‑year.
• Director Jeffrey Stein purchased 50,000 shares at $32.96, and while insiders own 2.50% of the stock, institutional investors hold roughly 98.29%.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seventeen ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $50.4375.

IDYA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. UBS Group initiated coverage on IDEAYA Biosciences in a report on Wednesday, January 7th. They issued a "buy" rating and a $50.00 price objective on the stock. The Goldman Sachs Group upped their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, April 14th. Citigroup upped their target price on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of IDEAYA Biosciences in a research report on Tuesday, April 21st.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $28.74 on Thursday. The stock's 50-day moving average is $32.07 and its two-hundred day moving average is $32.97. IDEAYA Biosciences has a 1-year low of $16.82 and a 1-year high of $39.28. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -17.96 and a beta of -0.04.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.10). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. During the same quarter last year, the business posted ($0.82) EPS. IDEAYA Biosciences's revenue for the quarter was down 39.4% compared to the same quarter last year. Equities research analysts anticipate that IDEAYA Biosciences will post -3.97 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey Stein bought 50,000 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the transaction, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds have recently added to or reduced their stakes in IDYA. Iron Triangle Partners LP acquired a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at approximately $7,347,000. General American Investors Co. Inc. lifted its holdings in shares of IDEAYA Biosciences by 7.7% in the 3rd quarter. General American Investors Co. Inc. now owns 280,261 shares of the company's stock valued at $7,626,000 after buying an additional 20,000 shares during the period. Candriam S.C.A. lifted its holdings in shares of IDEAYA Biosciences by 10.8% in the 3rd quarter. Candriam S.C.A. now owns 1,012,967 shares of the company's stock valued at $27,563,000 after buying an additional 98,567 shares during the period. Cinctive Capital Management LP lifted its holdings in shares of IDEAYA Biosciences by 193.9% in the 3rd quarter. Cinctive Capital Management LP now owns 49,946 shares of the company's stock valued at $1,359,000 after buying an additional 32,953 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of IDEAYA Biosciences by 174.0% in the 3rd quarter. Envestnet Asset Management Inc. now owns 299,032 shares of the company's stock valued at $8,137,000 after buying an additional 189,877 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.